Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting EGFR in bladder cancer.

G J Villares1, M Zigler, K Blehm

  • 1Department of Cancer Biology, U.T. MD Anderson Cancer Center, Houston, TX, USA.

World Journal of Urology
|August 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene Body Methylation of the Lymphocyte-Specific Gene <i>CARD11</i> Results in Its Overexpression and Regulates Cancer mTOR Signaling.

Molecular cancer research : MCR·2021
Same author

ATP11B mediates platinum resistance in ovarian cancer.

The Journal of clinical investigation·2021
Same author

MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.

Oncoimmunology·2020
Same author

Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.

JAMA dermatology·2020
Same author

Epigenetic profiling demarcates molecular subtypes of muscle-invasive bladder cancer.

Scientific reports·2020
Same author

Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Nature communications·2020
Same journal

Holmium laser enucleation of the prostate as salvage therapy for benign prostatic obstruction after multiple prior surgical interventions.

World journal of urology·2026
Same journal

Testing reliability of pubourethral ligament hemostat forceps support test for diagnosis of stress incontinence.

World journal of urology·2026
Same journal

Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis.

World journal of urology·2026
Same journal

Intrarenal pressure and clinical outcomes during suction-assisted versus conventional percutaneous nephrolithotomy: a systematic review and meta-analysis.

World journal of urology·2026
Same journal

AI-driven model for early failure prediction after HIFU integrating immediate post-ablation ultrasound and clinical data.

World journal of urology·2026
Same journal

Comment on "Nurse-led postoperative telemonitoring program following outpatient urethroplasty: a pilot study".

World journal of urology·2026
See all related articles

EGFR mutations and EGFRvIII expression are rare in bladder cancer, suggesting these alterations do not drive tumor growth. This finding impacts targeted therapy selection for urothelial carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) alterations, including mutations and overexpression, are implicated in various solid tumors.
  • EGFR mutations and the variant EGFRvIII are linked to patient response to targeted therapies like gefitinib.
  • Urothelial carcinoma's potential reliance on EGFR alterations necessitates investigation.

Purpose of the Study:

  • To investigate the presence and significance of EGFR kinase domain mutations and EGFRvIII expression in urothelial carcinoma.
  • To determine if these EGFR alterations contribute to the malignant phenotype of bladder cancer.
  • To inform therapeutic strategies involving tyrosine kinase inhibitors for urothelial carcinoma.

Main Methods:

  • Automated sequencing of the EGFR kinase domain (exons 18-21) in 11 bladder cancer cell lines and 75 patient tumors.

Related Experiment Videos

  • Immunohistochemistry to detect EGFRvIII expression in urothelial carcinoma tissue microarrays.
  • Validation of EGFRvIII detection using reverse transcription PCR, real-time PCR, and western blot analysis.

    • Main Results:

    • No EGFR kinase domain mutations were detected in any of the tested bladder cancer cell lines or patient tumors.
    • Initial immunohistochemistry suggested EGFRvIII expression in nearly half of patient samples.
    • Subsequent validation by RT-PCR, real-time PCR, and western blot confirmed the absence of EGFRvIII in all tested samples.

    Conclusions:

    • Mutations within the EGFR tyrosine kinase domain are rare in bladder cancer.
    • EGFRvIII expression is also not detected in urothelial carcinoma, despite initial immunohistochemistry findings.
    • These EGFR alterations do not appear to be significant drivers of bladder cancer, influencing the choice of targeted therapies.